

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) **EP 1 083 177 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

14.03.2001 Bulletin 2001/11

(51) Int. Cl.⁷: **C07D 487/04**, A61K 31/407,
A61K 31/4178, A61P 35/00,
A61P 43/00

(21) Application number: **00907992.2**

(22) Date of filing: **10.03.2000**

(86) International application number:
PCT/JP00/01461

(87) International publication number:
WO 00/58312 (05.10.2000 Gazette 2000/40)

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

• **Tao, Zhi-Fu**
Charlottesville, VA 22901 (US)
• **Saito, Isao**
Kyoto-shi, Kyoto 607-8242 (JP)

(30) Priority: **26.03.1999 JP 8359199**

(71) Applicant:

**Japan Science and Technology Corporation
Kawaguchi-shi, Saitama 332-0012 (JP)**

(74) Representative:

**Cresswell, Thomas Anthony
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5LX (GB)**

(72) Inventors:

• **Sugiyama, Hiroshi**
Shinjuku-ku, Tokyo 162-0842 (JP)

(54) **COMPOUNDS CAPABLE OF CLEAVING DOUBLE-STRANDED DNA AND METHOD OF UTILIZATION OF THE SAME**

(57) Novel chemical species capable of simultaneously alkylating double-stranded DNA and cleaving the same; methods for alkylating and cleaving DNA by using these species; and anticancer agents with the use of these compounds. Compounds represented by the following general formula (I) which are capable of simultaneously alkylating double-stranded DNA and cleaving the same; a method for alkylating DNA and a method for cleaving double stranded DNA by using these compounds; and medicinal compositions with the use of these compounds: B-L-A (I) wherein B represents a chemical structure capable of recognizing the base sequence of DNA, for example, optionally substituted pyrrole-imidazole polyamide; A represents a chemical structure capable of binding to one base of DNA, for example, the alkylation moiety of duocarmycin A; and L represents a linker capable of binding the chemical structures A and B, for example, vinyl.

EP 1 083 177 A1

THIS PAGE BLANK (USPTO)

DescriptionTechnical Field

- 5 [0001] The present invention relates to a compound, which can be produced by chemical synthesis and can simultaneously alkylating and cleaving a double-strand DNA, a method for alkylating DNA using compound thereof, a method for cleaving double-strand DNA, and a pharmaceutical composition using compound thereof.

Background Art

- 10 [0002] Base sequence of total gene, our human "blue print of life" is under elucidation by the human genome project within few years. The fact that the disease or the aging will occur, if this blue print is damaged or acquires the damage, is well known. As a result of progress in the human genome project, many diseases including cancer can be understood in the DNA level and the total medical science including diagnosis and prophylaxis may be changed revolutionarily. Further, a therapeutic method based on understanding in the DNA level of these diseases, namely development of pharmaceutical products targeting causal gene of disease and its product is highly expected, however mediatory studies for applying the fundamental studies to the clinical studies have only been just started. Anticancer agents used at present are antibiotics mainly selected by screening, and are originally not produced by microorganisms for the purpose of their cytotoxic action for cancer cells, and among them, almost no substances based on molecular biological knowledge of cancer are known. If expression of the intracellular specific gene can be freely controlled extracellularly, ultimate therapeutic method in the gene level can be achieved.

- 15 [0003] Recently, we have found that antibiotic duocarmycin constructed heterodimer with a molecule of the other species such as distamycin to achieve cooperatively molecular recognition of DNA, and effective alkylation of base sequence can be achieved as compared with the case of duocarmycin alone (Proc. Natl. Acad. Sci. USA 93, 14405, 25 1996). Based on the result of the discovery, pyrrole-imidazole polyamide is bound with the alkylation site of duocarmycin as a DNA recognition site and we have successfully synthesized the molecule which can selectively alkylating DNA at any base sequences (Japanese Patent Application No. Hei 10-260710). However, the compounds only binding with pyrrole-imidazole polyamide as the DNA recognition site in the alkylating moiety of duocarmycin can not only have insufficient alkylation activity but also alkylate only one strand base sequence.

- 30 [0004] We have examined alkylation reaction with these molecules and DNA using computer modeling such as molecular dynamics of these compounds in detail, and found that as a result of the insertion of the linker such as vinyl group into the location of the cyclopropane moiety (segment A), which was a reactive site of duocarmycin, an improved alkylation efficacy of DNA could be expected.

35 Disclosure of Invention

- [0005] The present invention provides alkylating agent with improved efficiency of DNA alkylation. Further, we have found in the present study that the alkylating agent of the present invention showed dimer-like behavior as well as simultaneously alkylating and cleaving the double-strand DNA, and had an action as the artificial restriction enzyme for the 40 specific base sequence.

- [0006] Consequently, the present invention provides novel chemical species, which can simultaneously alkylating and cleaving the double-strand DNA. Further, the present invention provides a method for alkylating and cleaving DNA using chemical species thereof.

- 45 [0007] The present invention further provides anticancer agent using compound thereof.

Brief Description of Drawing[0008]

- 50 Fig. 1 is a drawing replaced by photograph showing result of a reaction with ImPyLDu86 of the present invention and DNA.

Fig. 2 shows base sequence of DNA and a chemical structure of ImPyLDu86 used in the experiment.

Fig. 3 is a schematic representation of cleavage site of DNA by a compound of the present invention.

55 Best Mode for Carrying Out the Invention

- [0009] The present invention relates to a compound, which can simultaneously cleave double-strand of DNA, represented by the general formula (I)

wherein B is a chemical structure which can recognize base sequence of DNA, A is a chemical structure which can bind with a base of DNA, and L is a linker which can link with chemical structures of A and B.

5 [0010] Further, the present invention relates to a method for alkylating the specific part of base sequence of the double-strand DNA and a method for cleaving the specific part of base sequence of the double-strand DNA comprising using the compound hereinabove.

[0011] The present invention further relates to a pharmaceutical composition using these compounds, especially an anticancer agent


10 [0012] A chemical structure moiety B, which can recognize base sequence of DNA, in the above general formula (I) of the present invention is preferably the chemical structure derived from optionally substituted pyrrole and/or imidazole. Substituents in pyrrole and imidazole are not limited, if these substituents do not inhibit to recognize base sequence of DNA. Examples of substituents are straight or branched alkyl having carbon atoms 1-10, preferably 1-5, alkoxy derived from the above alkyl, hydroxyl, amino, N-alkyl substituted amino derived from the above alkyl, N-acylamino derived from organic carboxylate, guanidino and substituted guanidino. Examples are N-methylpyrrole, N-methylimidazole, 3-hydroxypyrrole and N-methyl-3-hydroxypyrrole.

[0013] The chemical structural moiety B, which can recognize base sequence of DNA, is preferably, with more concretely, pyrrole-imidazole polyamide. Length (numbers) of pyrrole and imidazole are not limited, and are 2-10, preferably 2-5.


20 [0014] The chemical structural moiety A, which can bind with a base of DNA, is preferably the chemical structure having cyclopropane ring, and is more preferably alkylating moiety of duocarmycin.

[0015] The linker moiety L, which can link with chemical structures A and B, is preferably a chemical structure having an interval with proper distance between the segment A and the segment B, without losing alkylating activity. Preferable example is a chemical structure having vinyl group.

25 [0016] The compound of the present invention represented by the general formula (I) is preferably a compound represented by the following formula (hereinafter designates as "PyPyLDu86"):



40 or a compound represented by the formula (hereinafter designates as "ImPyLDu86"):




55 [0017] The above compounds recognize abase sequence TGACG or CGACG, or complementary strand thereof.

[0018] The compound represented by the general formula (I) of the present invention can be produced according to a known method. Namely, A-segment and B-segment are produced by the conventional method, and a linker seg-

ment L is bound with the above segment A or B, and the remaining segment is subsequently bound thereto.

[0019] Examples of production of the above ImPyLDu86 (7a) and PyPyLDu86 (7b) are shown in the following chemical reaction scheme. Numbers below each compound in the reaction scheme indicate compound No.



[0020] Each reaction indicates as follows: a) a treatment with benzotriazole-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (BOP) and NaBH₄ in THF; b) a treatment with MnO₂ in THF; c) a treatment with triethyl phosphonoacetate and NaH in THF; d) a treatment with sodium hydroxide in water-methanol; e) a treatment with 1,1'-carbonyldiimidazole in DMF; and f) a treatment with segment A of DU86 using NaH in DMF.

[0021] Reactivities of the thus synthesized PyPyLDu86 and ImPyLDu86 with DNA were investigated. Result of alkylation using ImPyLDu86 is shown in Fig. 1. DNA used in this experiment and a structure of ImPyLDu86 used are shown in Fig. 2.

[0022] The left electrophoresis pattern is a result of the upper strand of the double-strand DNA, and the right electrophoresis pattern is a result of the lower strand of the double-strand DNA. Alkylating site can be observed by thermally induced strand cleavage. As a result, the double-strand DNA is mainly cleaved at the site 1 and the site 2 of the two strands from the lower concentration, and simultaneous alkylation on the two strands can be confirmed. No compounds have been known to occur such the cleavage, and in this sense, the compound of the present invention can be said as an artificial restriction enzyme. The efficiency of cleavage was found to approach high ratio of 70% calculated by an amount of used ImPyLDu86, and is unusually high efficiency as compared with that of the previously synthesized molecule (refer to Japanese Patent Application No. Hei 10-260710).

[0023] A reason for occurring simultaneous alkylation on the two strands may be, as shown in Fig. 3, that a dimerization of ImPyLDu86 recognizes GC base pair by constructing preferable stacking of the linker moiety and imidazole, and specifically binds with recognition sequence on the double-strand DNA. As the results, it was demonstrated that the linker, which was proposed and inserted by the molecular design, could increase the reactivity of the compound and could be applied as a recognition unit by pairing with imidazole. Based on these knowledge, we can say that we have taken a step toward the molecular design of the new type of drugs for gene therapy targeting on the specific sequence of DNA.

[0024] Cytotoxic activity of the compound of the present invention based on the properties described hereinbefore

was examined. Cytotoxic activities of PyPyLDu86 and ImPyLDu86 of the present invention and known anticancer agent duocarmycin on HeLaS₃ cells (uterocervical squamous cell carcinoma cells) were tested. Results are shown in Table 1. the result indicates that the compounds of the present invention have approximately 3 - 7-fold activities as compared with duocarmycin.

- 5 [0025] The compound of the present invention is useful for anticancer agent and can be prepared as a pharmaceutical composition with addition of pharmaceutically acceptable carrier. The compound of the present invention can be administered orally or parenterally depending on symptoms. Effective dose of the pharmaceutical composition of the present invention can be selected, although depending on conditions and symptoms of patients, generally within a range of 1 µg - 100 mg/kg/day. The pharmaceutical composition of the present invention can be formulated by conventional method for the preparation for injection.

Examples

- 15 [0026] Following examples illustrate the present invention more concretely, but the present invention is not construed as limiting within these examples.

[0027] Abbreviations of reagents used in the following examples are as follows.

- 20 DIEA: N,N-diisopropylethylamine,
DMF: N,N-dimethylformamide,
THF: tetrahydrofuran and
BOP: benzotriazole-1-yloxytris (dimethylamino)-phosphonium hexafluorophosphate.

[0028] In the following examples, reactions were monitored by thin-layer chromatography (TLC) using 025 mm silica gel 60 plates impregnated with 254 nm fluorescent indicator (Merck). TLC plates were visualized by UV light.

- 25 [0029] In NMR spectra, tetramethylsilane was used as the internal standard, and chemical shifts of ¹H-NMR spectra were recorded in ppm.

30 [0030] EI (Electron impact) mass spectra were recorded on a JNM-AX 505, and ESIMS (Electrospray ionization mass spectra) was recorded on a PE SCIEX API 165. Ex Taq DNA polymerase and filter tube (Suprec-02) were purchased from Takara Shuzo Co., thermo sequenase core sequencing kit and loading dye (dimethylformamide with fushin red) from Amersham Co., 5'-end Texas Red-modified DNA oligomer (18mer) from Kurabo Co., and 50% Long Ranger gel solution from FMC Bioproducts. Polyacrylamide gel electrophoresis was performed on a HITACHI 5500-S DNA sequencer.

Example 1: Production of compound 2a (X = N)

- 35 [0031] NaBH₄ 98 mg (2.59 mmol) was added to a solution of 204.8 mg (0.67 mmol) of compound 1a, BOP 326.3 mg (0.74 mmol) and DIEA 170 µl in THF 30 ml. The reaction mixture was stirred for 3 hours at room temperature and solvent was distilled off in vacuo to give a residue, to which CH₃OH 20 ml and water 5 ml were added. The solution was stirred for 1 hour to obtain a clear solution. The solvents were removed in vacuo, and the resultant yellow residue was purified by flash chromatography using CH₃OH and CH₂Cl₂ to obtain the objective compound 2a 92.6 mg, yield 47.4%.

¹H NMR (DMSO-d₆) δ

- 45 10.24 (s, 1H), 9.62 (s, 1H), 7.38 (s, 1H), 7.10 (d, J=2.0Hz, 1H), 6.09 (d, J=2.0Hz, 1H), 4.86 (t, J=5.5Hz, 1H), 4.34 (d, J=5.5Hz, 2H), 3.93 (s, 3H), 3.54 (s, 3H), 2.01 (s, 3H).

Example 2: Production of compound 2b (X = CH)

[0032] Compound 2b was obtained in yield 68.5% in a similar manner as the compound 2a.

50 ¹H NMR (DMSO-d₆) δ

- 9.76 (s, 1H), 9.64 (s, 1H), 7.10 (d, J=2.0Hz, 1H), 7.05 (d, J=2.0Hz, 1H), 6.78 (d, J=2.0Hz, 1H), 6.01 (d, J=2.0Hz, 1H), 4.82 (t, J=5.5Hz, 1H), 4.34 (d, J=5.5Hz, 2H), 3.80 (s, 3H), 3.53 (s, 3H), 1.96 (s, 3H).

Example 3: Production of compound 3a (X = N)

- 55 [0033] A mixture of 85 mg (0.29 mmol) of compound 2a and activated MnO₂ (85%) 550 mg was added in THF 30 ml, and the mixture was stirred at room temperature for 1.5 hour and filtered. The residue obtained by removal of solvent in vacuo was analyzed by ¹H NMR to confirm that the residue had sufficient purity for use in the next reaction step

without further purification.

¹H NMR (DMSO-d₆) δ

10.21 (s, 1H), 10.18 (s, 1H), 9.50 (s, 1H), 7.63 (s, 1H), 7.43 (s, 1H), 7.10 (d, J=2.0Hz, 1H), 3.94 (s, 3H), 2.84 (s, 3H), 2.02 (s, 3H).

Example 4: Production of compound 3b (X = CH)

[0034] Compound 3b was obtained in yield 68.5% in a similar manner as the compound 3a.

¹H NMR (DMSO-d₆) δ

9.99 (s, 1H), 9.80 (s, 1H), 9.49 (s, 1H), 7.57 (s, 1H), 7.14 (d, J=1.0Hz, 1H), 6.98 (d, J=1.0Hz, 1H), 6.88 (d, J=2.0Hz, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 1.97 (s, 3H).

Example 5: Production of compound 4a (X = N)

[0035] NaH (60%) 23.1 mg (0.58 mmol) was dissolved in THF 6 ml, and triethyl phosphonoacetate 116 ml was added thereto under ice cooling. The reaction mixture was stirred for 5 minutes, and a solution of compound 3a dissolved in THF 25 ml was added thereto. The resulting mixture was stirred for overnight THF was distilled off in vacuo. The obtained residue was subjected to flash chromatography using ethyl acetate. Compound 4a was obtained as yellow solid 88.5 mg in yield 84% (yield of two steps based on 2a).

¹H NMR (DMSO-d₆) δ

10.25 (s, 1H), 9.87 (s, 1H), 7.51 (d, J=15.9Hz, 1H), 7.44 (d, J=1.8Hz, 1H), 7.42 (s, 1H), 6.84 (d, J=1.8Hz, 1H), 6.11 (d, J=15.9Hz, 1H), 4.16 (q, J=7.0Hz, 2H), 4.13 (s, 3H), 3.70 (s, 3H), 2.02 (s, 3H), 1.24 (t, J=7.0Hz, 3H).

Example 6: Production of compound 4b (X = CH)

[0036] Compound 4b was obtained in yield 55% in a similar manner as the compound 4a.

¹H NMR (DMSO-d₆) δ

9.87 (s, 1H), 9.78 (s, 1H), 7.51 (d, J=15.5Hz, 1H), 7.39 (d, J=2.0Hz, 1H), 7.13 (d, J=2.0Hz, 1H), 6.85 (d, J=2.0Hz, 1H), 6.73 (d, J=2.0Hz, 1H), 6.07 (d, J=15.5Hz, 1H), 4.16 (q, J=7.0Hz, 2H), 3.82 (s, 3H), 3.68 (s, 3H), 1.97 (s, 3H), 1.23 (t, J=7.0Hz, 3H).

Example 7: Production of compound 5a (X = N)

[0037] 2N dil. NaOH 1.5 ml and water 3 ml were added to a solution of 70 mg (0.2 mmol) of compound 4a in CH₃OH 5 ml. The mixture was stirred at room temperature for 4.5 hours.

[0038] After removal of solvent by vacuum distillation, water 20 ml was added to the residue. The resulting solution was filtered, and the filtrate was acidified with 2N HCl to pH2 - 3. The thus obtained gel-like precipitate was collected by filtration and dried to obtain 43 mg of compound 5a in yield 67%.

¹H NMR (DMSO-d₆) δ

10.24 (s, 1H), 9.84 (s, 1H), 7.43 (d, J=15.0Hz, 1H), 7.41 (s, 1H), 7.40 (s, 1H), 6.78 (s, 1H), 6.03 (d, J=15.0Hz, 1H), 3.94 (s, 3H), 3.67 (s, 3H), 3.86 (s, 3H);

ESIMS m/e

As C ₁₅ H ₁₆ N ₅ O ₄ ;	Calculated value (M-H)	330.3
	Observed value	330.2

Example 8: Production of compound 5b (X = CH)

[0039] Compound 5b was obtained in yield 57% in a similar manner as the compound 5a.

¹H NMR (DMSO-d₆) δ

9.83 (s, 1H), 9.78 (s, 1H), 7.38 (d, J=16.0Hz, 1H), 7.34 (s, 1H), 7.13 (d, J=2.0Hz, 1H), 6.84 (d, J=2.0Hz, 1H), 6.64 (s, 1H), 5.99 (d, J=16.0Hz, 1H), 3.82 (s, 3H), 3.65 (s, 3H), 1.99 (s, 3H);

5 ESIMS m/e

10

As C ₁₆ H ₁₇ N ₄ O ₄ ;	Calculated value (M-H)	329.3
	Observed value	329.4

Example 9: Production of compound 6a (X = N)

15 [0040] 1,1'-carboxyldiimidazole 49.9 mg (0.31 mmol) was added to a solution of 26.4 mg (0.08 mmol) of compound 5a in DMF 2ml. The reaction mixture was stirred overnight at room temperature, and water 20 ml was added. The mixture was filtered to obtain 20.5 mg of compound 6a as yellow precipitate in yield 68%.

¹H NMR (DMSO-d₆) δ

20 10.23 (s, 1H), 10.04 (s, 1H), 8.67 (s, 1H), 7.90 (d, J=1.0Hz, 1H), 7.88 (d, J=15.5Hz, 1H), 7.50 (d, J=2.0Hz, 1H), 7.44 (s, 1H), 7.32 (d, J=2.0Hz, 1H), 7.16 (d, J=15.5Hz, 1H), 7.10 (s, 1H), 3.96 (s, 3H), 3.79 (s, 3H), 2.03 (s, 3H);

ESIMS m/e

25

As C ₁₈ H ₁₈ NO ₃ ;	Calculated value (M-H)	380.4
	Observed value	380.4

30

Example 10: Production of compound 6b (X = CH)

[0041] Compound 6b was obtained in yield 80% in a similar manner as the compound 6a.

35 ¹H NMR (DMSO-d₆) δ

10.1 (s, 1H), 9.82 (s, 1H), 8.68 (s, 1H), 7.91 (t, J=2.0 and 2.0Hz, 1H), 7.87 (d, J=15.0Hz, 1H), 7.48 (d, J=2.0Hz, 1H), 7.22 (d, J=2.0Hz, 1H), 7.16 (d, J=1.5Hz, 1H), 7.14 (d, J=15.0Hz, 1H), 7.10 (s, 1H), 6.89 (d, J=1.5Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 1.97 (s, 3H);

ESIMS m/e

40

As C ₁₉ H ₁₉ N ₆ O ₃ ;	Calculated value (M-H)	379.4
	Observed value	379.4

45

Example 11: Production of compound 7a (X = N)

50 [0042] A solution of 6.1 mg (0.024 mmol) of segment A of DU86 dissolved in DMF 0.3 ml was added to a solution of sodium hydride (60%) 3.2 mg (0.08 mmol) dissolved in DMF 0.3 ml at -50°C. The mixture was stirred at -50 to -40°C for 3 hours. After a solution of 10.8 mg (0.028 mmol) of compound 6a dissolved in DMF 1 ml was added at -50°C, the reaction mixture was further stirred at -40°C for 5 hours, and allowed to stand at -30°C in a refrigerator for 2 days. Then sodium phosphate buffer (0.01 M) 3 ml was added, and the mixture was stirred at room temperature for 5 minutes. The yellow residue obtained by distilled off the solvent in vacuo was purified by flash chromatography using CH₃OH and
55 CHCl₃ to obtain 12.3 mg of compound 7a in yield 91%.

¹H NMR (DMSO-d₆) δ

12.36 (s, 1H), 10.24 (s, 1H), 9.97 (s, 1H), 7.58 (d, J=15.0Hz, 1H), 7.43 (s, 1H), 7.41 (d, J=2.0Hz, 1H), 6.99

(d, J=2.0Hz, 1H), 6.85 (s, 1H), 6.58 (d, J=15.0Hz, 1H), 4.29 (d, J=10.5Hz, 1H), 4.19 (dd, J=5.0Hz and 4.5Hz, 1H), 3.95 (s, 3H), 3.73 (s, 3H), 3.72 (s, 3H), 3.46 (m, 1H), 2.47 (s, 3H), 2.08 (m, 1H), 2.02 (s, 3H), 1.29 (t, J=4.5 and 3.5Hz, 1H);
ESIMS m/e

As C ₂₉ H ₂₈ N ₇ O ₆ ;	Calculated value (M-H)	570.6
	Observed value	570.4

Example 12: Production of compound 7b (X = CH)

[0043] Compound 7b was obtained in yield 77% in a similar manner as the compound 7a.

¹H NMR (DMSO-d₆) δ

12.36 (s, 1H), 9.90 (s, 1H), 9.80 (s, 1H), 7.57 (d, J=15.0Hz, 1H), 7.38 (d, 1.5Hz, 1H), 7.14 (d, J=2.0Hz, 1H), 6.88 (d, 1.5Hz, 1H), 6.86 (d, J=2.0Hz, 1H), 6.84 (s, 1H), 6.56 (d, J=15.0Hz, 1H), 4.29 (d, J=10.5Hz, 1H), 4.19 (dd, J=4.0 and 4.5Hz, 1H), 3.83 (s, 3H), 3.73 (s, 1H), 3.71 (s, 1H), 3.46 (m, 1H), 2.47 (s, 3H), 2.09 (m, 1H), 1.97 (s, 3H), 1.29 (t, J=4.5 and 3.5Hz, 1H);
ESIMS m/e

As C ₃₀ H ₂₉ N ₆ O ₆ ;	Calculated value (M-H)	569.6
	Observed value	569.5

Example 13: Alkylation of 450 bp DNA fragments

(1) Preparation of 5'-texas red-end-modified 450 bp DNA fragment

[0044] The 5'-end texas red-modified 450 bp DNA fragments pUC18 F780*-1229 and pUC18 R1459*-1908 (these are complementary) were prepared by the PCR method using 5'-end texas red-modified 18mers as primers and purified by filtration using Suprec-02. The concentration was determined by ethidium bromide staining. The asterisk (*) indicates texas red modification site, and numerals indicates nucleotide numbering from the replication origin.

(2) High-resolution gel electrophoresis

[0045] A standard reaction mixture containing 5'-end texas red-labeled DNA fragment 60 nM, DMF 5% (v/v) and various concentrations of drugs in total 10 µl of sodium phosphate buffer (pH 7.0) 12.5 mM was added into microcentrifugal tube (Eppendorf tube) and allowed to stand at room temperature for overnight. Calf thymus DNA (5 mM, 1 µl) was added thereto and heated at 90°C for 5 minutes. DNA was collected by ethanol precipitation. The thus obtained DNA was dissolved in loading dye (DMF solution of fushin red) 8 µl. The sample solution was heated at 94°C for 20 minutes for denaturation of DNA, and immediately cooled to 0°C. A 2 µl of aliquot was electrophoresed on polyacrylamide gel using 6% Long Ranger (trademark) gel solution using 5500-S DNA sequencer system.

Example 14: Growth inhibitory test on HeLaS₃ cells

[0046] Suspension 0.75 ml of HeLaS₃ cells, 2.67 × 10⁴ cells/ml, in MEM medium containing 10% fetal bovine serum and 2 mM glutamine, was dispensed into each well in 24 cell culture plate. After incubation in the CO₂-incubator at 37°C for overnight, 0.25 ml portions of each test compound shown in Table 1, which was appropriately diluted with medium, was added into each well.

[0047] After cells were incubated for 72 hours in the CO₂-incubator, the culture supernatant was removed, and cells were dispersed using trypsin-ethylenediaminetetraacetic acid (EDTA) and collected. Cell counts were counted by cell counter, and cell counts without treatment and cell counts treated with known concentration of test compound were compared to calculate the concentration of test compound which inhibits 50% of cell growth (IC₅₀). Results are shown in the following table.

Test Compound	IC ₅₀ (nM)
PyPyLDu86	1.5
ImPyLDu86	0.7
Duocarmycin	4.7

Industrial Applicability

[0048] The present invention provides chemically synthesized compound, which can simultaneously alkylating or cleaving double-strand DNA. The compound is not only useful for artificial restriction enzyme but also useful for gene therapy targeting the specific base sequence.

SEQUENCE LISTING

<110> Japan Science And Technology Corporation

<120> Compounds capable of cleaving double-stranded DNA and method of utilisation of the same

<130> N80828

<140> 00907992.2 (PCT/JP00/01461)

<141> 2000-3-10

<150> JP 11-83591

<151> 1999-3-26

<160> 2

<210> 1

<211> 450

<212> DNA

<213> pUC 18

<400> 1

```

agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa      60
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca      120
caaaaatcga cgctcaagtc agagggtggc aaaccgcaca ggactataaa gataccaggc      180
gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata      240
cctgtccgcc tttctccctt cggaagcgt ggcgctttct caatgctcac gctgtaggta      300
tctcagttcg gtgtaggtcg ttctctccaa gctgggctgt gtgcacgaac cccccgttca      360
gcccgaaccg tgcgccttat ccggttaacta tcgtcttgag tccaaccggt taagacacga      420
cttatcgcca ctggcagcag ccactggtaa                                     450

```

<210> 2

<211> 450

<212> DNA

<213> pUC 18

<400> 2

```

tcttagtccc ctattgcgtc ctttcttgta cactcgtttt ccggtcgttt tccggtcctt      60
ggcatttttc cggcgcaacg accgcaaaaa ggtatccgag gcggggggac tgctcgtagt      120
gttttttagct gcgagttcag tctccaccgc tttgggctgt cctgatattt ctatgggtccg      180
caaaggggga ccttcgaggg agcacgcgag aggacaaggc tgggacggcg aatggcctat      240
ggacaggcgg aaagagggaa gcccttagca ccgcgaaaga gttacgagtg cgacatccat      300
agactcaagc cacatccagc aagcgagggt cgacccgaca cacgtgcttg gggggcaagt      360
cgggctggcg acgcgggaata ggccattgat agcagaactc aggttgggac attctgtgct      420
gaatagcggg gaccgtcgtc ggtgaccatt                                     450

```

Claims

- 5 1. A compound which compound can simultaneously cleave double-strand of DNA, represented by the general formula (I)




10 wherein B is a chemical structure which can recognize base sequence of DNA, A is a chemical structure which can bind with a base of DNA, and L is a linker which can link with a chemical structures of A and B.

2. The compound according to claim 1 wherein the chemical structure which can recognize the base sequence of DNA, and the chemical structure is derived from optionally substituted pyrrole and/or imidazole.


- 15 3. The compound according to claim 1 or 2 wherein the chemical structure which can bind with abase of DNA, and the chemical structure has cyclopropane ring.

- 20 4. The compound according to any one of claims 1 - 3 wherein the linker which can link with chemical structures of A and B, and the linker is a chemical structure having vinyl group.

5. The compound according to any one of claims 1 - 4 wherein the compound of the formula (I) is a compound represented by the following formula.



OR



6. A method for alkylating the specific part of base sequence of the double-strand DNA comprising using the compound according to any one of claims 1 - 5.

7. A method for cleaving the specific part of base sequence of the double-strand DNA comprising using the compound according to any one of claims 1 - 5.
- 5 8. The method according to claims 6 or 7 wherein the specific base sequence is TGACG or CGACG, or complementary strand thereof.
9. A pharmaceutical composition comprising the compound according to any one of claims 1 - 5 and a pharmaceutically acceptable carrier thereof.
- 10 10. The pharmaceutical composition according to claim 9 wherein the composition is a remedy for cancer.

15

20

25

30

35

40

45

50

55

Fig. 1





Fig. 2



5'- AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA GGCCAGCAAA
 3'- TCTTAGTCCC CTATTGCGTC CTTTCTTGTA CACTCGTTTT CCGGTCGTTT

AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC
 TCCGGTCCTT GGCATTTTTT CCGCGCAACG ACCGCAAAAA GGTATCCGAG

Site 1 ↓ Site 2 ↓
 CGCCCCCTG ACGAGCATCA CAAAATCGA CGCTCAAGTC AGAGGTGGCG
 GCGGGGGGAC TGCTCGTAGT GTTTTAGCT GCGAGTTCAG TCTCCACGCG

AAACCCGACA GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC
 TTTGGGCTGT CCTGATATTT CTATGGTCCG CAAAGGGGGA CCTTCGAGGG

TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC TTACCGGATA CCTGTCCGCC
 AGCACGCGAG AGGACAAGGC TGGGACGGCG AATGGCCTAT GGACAGGCGG

TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT CAATGCTCAC GCTGTAGGTA
 AAAGAGGGAA GCCCTTAGCA CCGCGAAAGA GTTACGAGTG CGACATCCAT


TCTCAGTTCC GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC
 AGACTCAAGC CACATCCAGC AAGCGAGGT CGACCCGACA CACGTGCTTG

CCCCCGTTCA GCCCGACCGC TCGCCTTAT CCGGTAACTA TCGTCTTGAG
 GGGGGCAAGT CCGGCTGGCG ACGCGGAATA GGCCATTGAT AGCAGAACTC


TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA-3'
 AGGTGGGGCC ATTCTGTGCT GAATAGCGGT GACCGTCGTC GGTGACCAAT-5'

Fig. 3

Site 1



Site 2



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/01461

A. CLASSIFICATION OF SUBJECT MATTER		
Int.Cl ⁷ C07D487/04, A61K31/407, 31/4178, A61P35/00, 43/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Int.Cl ⁷ C07D487/04, A61K31/407, 31/4178, A61P35/00, 43/00		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA (STN) REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	NOBUYOSHI AMISHIRO, SATORU NAGAMURA, EIJI KOBAYASHI, AKIHIKO OKAMOTO, KATSUSHIGE GOMI, HIROMITSU SAITO, "Synthesis and Antitumor Activity of Duocarmycin Derivatives: A-Ring Pyrrole Compounds Bearing 5-Membered Heteroarylacryloyl Groups", Chemical & Pharmaceutical Bulletin, 1999, Vol.47, No.10, p.1393-1403	1-10
A	WO, 97/44000, A2 (PANORAMA RESEARCH INC), 27 November, 1997 (27.11.97) & US, 5843937, A	1-10
A	WO, 96/23497, A1 (Synphar Laboratories, Inc.), 08 August, 1996 (08.08.96) & US, 5502068, A & EP, 800390, A1 & JP, 11-500427, A	1-10
A	NANCY L. FREGEAU, YUQIANG WANG, RICHARD T. PON, WILLIAM A. WYLIE, J. WILLIAM LOWN, "Characterization of a CPI-Lexitropsin Conjugate-Oligonucleotide Covalent Complex by 1H NMR and Restrained Molecular Dynamics Simulation", Journal of the American Chemical Society, 1995, Vol.117, No.35, p.8917-8925	1-10
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 13 April, 2000 (13.04.00)		Date of mailing of the international search report 25 April, 2000 (25.04.00)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/01461

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-4,6-10
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
- Although the contents of the description and common general technical knowledge at the point of the application are taken into consideration, it cannot be technically understood what substantial meanings the compounds having the general formula B-L-A and being capable of simultaneously cleaving two strands of DNA have. Thus, International Search has been practiced exclusively on compounds 7a/7b (as set forth in claim 5), which can be understood based on the contents of the description, and methods and medicinal compositions with the use of these compounds.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

THIS PAGE BLANK (USPTO)